Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Cancer Immunotherapies Market to 2022, by Stage of Development, Forecasts

Monday, February 13, 2017 9:02
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Cancer is a group of diseases characterized by abnormal cell growth. It is a multi-step process, as a single mutation is almost certainly insufficient to cause a cell to become malignant. A number of cellular processes must be deregulated to allow cells to proliferate uncontrollably while evading apoptosis. Initially, key cell growth, proliferative and pro-apoptotic signaling pathways are deregulated in most cancers. These signaling pathways enable cell survival, continued proliferation, and the avoidance of programmed cell death.

It is now widely believed that many tumors express antigens that can be identified by the adaptive immune system, and that can therefore potentially be used to produce an anti-tumor immune response. The immune system is believed to have the greatest potential in terms of treating cancer, as there is evidence tumors are recognized by the immune system, and this tumor-specific immune response is due to the recognition of tumor antigens. However, in many cancers, disease progression is also accompanied by immune suppression, which hinders an effective anti-tumor response and tumor elimination.

For more information at http://www.reportsweb.com/global-cancer-immunotherapies-market-to-2022 .

The different types of cancer immunotherapies used to treat cancer include monoclonal antibodies (mAbs) directed at specific tumor-associated antigens (TAA); immune checkpoint inhibitors, which target key proteins involved in the immune response, such as programmed cell death-1 (PD-1); cancer vaccines, which can be used to stimulate an immune response in a patient; and non-specific immunotherapies, which are therapies that do not target cancer cells specifically, but stimulate the immune system in a more general way, such as interferon therapy.

Overall, there are 2,037 products in active development in the cancer immunotherapy pipeline. This makes it a notable portion of the entire oncology pipeline, and reflects the strong interest in this class of therapy in product development. This is due to growing clinical rationale behind developing such therapies, and the willingness of drug developers to invest in novel therapeutics, which will offer significant product differentiation from market competitors.

The leading indications in terms of cancer immunotherapy product development are breast cancer, melanoma, non-small-cell lung cancer (NSCLC) and ovarian cancer, which are the focus of this report. This is based on the high level of activity in terms of cancer immunotherapy product development in these specific oncology indications, with the aforementioned indications ranking highest in this regard.

Request Sample Copy: http://www.reportsweb.com/inquiry&RW00020762/sample .

Report Scope

The cancer immunotherapies market already consists of some commercially successful products. 
  – Which classes of drug dominate the market?
  – What additional benefits have newly approved therapies brought to the market?
The cancer immunotherapies pipeline is vast, with a significant degree of diversity in terms of molecule types and targets.
  – Which molecular targets appear most frequently in the pipeline?
  – What are the commercial prospects for the most promising late-stage pipeline products?
The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%.
  – Which products are forecast to drive this substantial degree of growth?
  – Will generic competition have a significant impact on the market over the forecast period?
The company landscape is growing increasingly competitive.
  – What are the leading companies in terms of market share?
  – Which companies are forecast to experience the greatest growth in market share? 
  – What are the drivers of growth for key companies in the market?
  – How dependent are the key companies on this disease cluster for revenue?
  – Which companies rely heavily on this disease cluster for revenue?

Make an enquiry: http://www.reportsweb.com/inquiry&RW00020762/buying .

Contact Us:

Call: +1-646-491-9876
Email: [email protected]

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.